ADVISORY, Feb. 09, 2015 (GLOBE NEWSWIRE) --
What:
Regulus Therapeutics Inc. (Nasdaq: RGLS ), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, will visit the Nasdaq MarketSite in Times Square.
In honor of the occasion, Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus will ring the Closing Bell.
Where:
Nasdaq MarketSite – 4 Times Square – 43 rd & Broadway – Broadcast Studio
When:
Tuesday, February 10, 2015 – 3:45 p.m. to 4:00 p.m. ET
Regulus Therapeutics Inc. Media Contact:
Amy Conrad
(858) 202-6321
aconrad@regulusrx.com
OR
Liz Bryan
Spectrum Science
(202) 955-6222 x2526
lbryan@spectrumscience.com
Nasdaq MarketSite:
Christine Barna
(646) 441-5310
Christine.Barna@nasdaq.com
Feed Information:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK
Social Media:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ .
For photos from ceremonies and events visit our Instagram Page: http://instagram.com/nasdaq
For news tweets, please visit our Twitter page at: http://twitter.com/nasdaq
For exciting viral content and ceremony photos visit Tumblr Page: http://nasdaq.tumblr.com/
Webcast:
A webcast of the Nasdaq Closing Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos:
To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.
About Regulus Therapeutics Inc. (Nasdaq: RGLS ) :
Regulus Therapeutics Inc. (Nasdaq: RGLS ) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a maturing microMarkers℠ biomarkers platform and a rich intellectual property estate to retain its domain dominant leadership in the microRNA field. Under its 'Clinical Map Initiative', Regulus is developing RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122 for the treatment of chronic hepatitis C virus infection, and RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy. Regulus is also advancing several programs toward clinical development in orphan disease indications, oncology and fibrosis. Regulus' commitment to innovation has resulted in multiple peer-reviewed publications in notable scientific journals and has resulted in the formation of strategic alliances with AstraZeneca and Sanofi and a research collaboration with Biogen Idec focused on microRNA biomarkers. Regulus maintains its corporate headquarters in La Jolla, CA. For more information, please visit http://www.regulusrx.com .
For more information, please visit http://www.regulusrx.com .
About Nasdaq:
Nasdaq (Nasdaq: NDAQ ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets. As the creator of the world’s first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,500 listed companies with a market value of over $8.8 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaq.com/ambition or www.nasdaqomx.com .
-NDAQA-
